Search Results for "Value-based%20price"

The administration has proposed a loophole in the Medicaid Best Price rules that would dismiss linking the drug's effectiveness to its price.

Research Data Analyst, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center

Several approaches that rewire existing reimbursement conventions as alternatives to facilitate ISP are proposed.

Steep increases in prices and spending on prescription drugs in the United States have triggered public outrage and questions about their value.

Value-based pricing has emerged as an alternative to prices determined by what the market will bear. But which agreements are truly "value-based"?

Dr. Peter Bach, alongside Kathy Sego, Dr. Douglas Holtz-Eakin, and Dr. Mark Miller, testified before U.S. Senate Finance Committee at its first hearing of the session, Drug Pricing in America: A Prescription for Change, Part I.

U.S. prices of common cardiovascular drugs are not consistent with the cost-effectiveness evidence.

The Drug Pricing Lab responds to the Trump Administration’s Request for Information on lowering drug prices with a summary of our findings.

A taxonomy of the features that make a payment model truly value-based.

Pharmaceutical manufacturers push for adoption of outcomes-based contracting as a means of achieving a value-based price, but such contracts are ill-suited to do so.

Drug Pricing Lab op-ed in STAT News discusses indication-specific pricing of Kymriah.

What steps are needed to make outcomes-based contracting a value-based approach?

John Arnold and Laura Arnold are donating $7.2 million to jumpstart innovative solutions that can better control rising pharmaceutical prices and provide more equitable access for all patients.

Turing Pharmaceutical's decision to raise the price of a drug by 5,000% not only sparked intense questions about the rationale for high prices on new and old medicines.

Value based pricing sounds great, but there's one big problem: it doesn't scale.